{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:51:21Z","timestamp":1788504681833,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prolactinomas are the most common type of pituitary adenomas, typically managed with dopamine agonists. However, some cases are refractory to standard therapies, posing significant clinical challenges. This case highlights the complexities of managing an aggressive macroprolactinoma resistant to conventional treatments and explores the use of immunotherapy as a novel intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 54-year-old male with a history of hypertension and type 2 diabetes mellitus presented with erectile dysfunction and low libido, leading to a diagnosis of prolactinoma. Over an 18-year period, he underwent multiple interventions, including cabergoline therapy, four transsphenoidal surgeries, radiation therapy, and various pharmacotherapies. Despite these, he had refractory disease with markedly elevated prolactin levels and tumor growth. In the final stages of the disease, pembrolizumab immunotherapy was attempted. Unfortunately, the patient\u2019s condition continued to deteriorate, ultimately leading to hospice care and death at the age of 71.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This case underscores the challenges associated with managing refractory prolactinomas and highlights the need for innovative therapeutic strategies, including immunotherapy. Further research is essential to establish the role of emerging treatments in improving outcomes for patients with aggressive pituitary adenomas.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40842-025-00218-8","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:03:22Z","timestamp":1744239802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An 18-year Odyssey: navigating the complex path of prolactinoma management: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Firdhous Alimathunisa","family":"Abdul Kather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafaq","family":"Khairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"9","key":"218_CR1","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023;108(9):2400\u201323. https:\/\/doi.org\/10.1210\/clinem\/dgad174. PMID: 36974474; PMCID: PMC10438891.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"218_CR2","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"218_CR3","doi-asserted-by":"publisher","unstructured":"Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, Gahete MD, EYRC (ENEA Young Researcher Committee). Aggressive and Malignant Prolactinomas. Neuroendocrinology. 2019;109(1):57\u201369. https:\/\/doi.org\/10.1159\/000497205. PMID: 30677777.","DOI":"10.1159\/000497205"},{"key":"218_CR4","doi-asserted-by":"publisher","unstructured":"Lasolle H, Ilie MD, Raverot G. Aggressive prolactinomas: how to manage? Pituitary. 2020;23(1):70\u201377. https:\/\/doi.org\/10.1007\/s11102-019-01000-7. PMID: 31617128.","DOI":"10.1007\/s11102-019-01000-7"},{"key":"218_CR5","doi-asserted-by":"publisher","first-page":"1204206","DOI":"10.3389\/fendo.2023.1204206","volume":"14","author":"C Lamas","year":"2023","unstructured":"Lamas C, C\u00e1mara R, Fajardo C, Remon-Ruiz P, Biagetti B, Guerrero-P\u00e9rez F, Araujo-Castro M, Mora M, Hanzu F, Iglesias P, Garc\u00eda-Centeno R, Soto A. Efficacy and safety of Temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Front Endocrinol (Lausanne). 2023;14:1204206. https:\/\/doi.org\/10.3389\/fendo.2023.1204206. PMID: 37720528; PMCID: PMC10500829.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"218_CR6","doi-asserted-by":"publisher","first-page":"bvab190","DOI":"10.1210\/jendso\/bvab190","volume":"6","author":"L Das","year":"2021","unstructured":"Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P. Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes. J Endocr Soc. 2021;6(2):bvab190. https:\/\/doi.org\/10.1210\/jendso\/bvab190. PMID: 35059545; PMCID: PMC8763612.","journal-title":"J Endocr Soc"},{"key":"218_CR7","doi-asserted-by":"publisher","first-page":"968692","DOI":"10.3389\/fendo.2022.968692","volume":"13","author":"S Du Four","year":"2022","unstructured":"Du Four S, Van Der Veken J, Duerinck J, Vermeulen E, Andreescu CE, Bruneau M, Neyns B, Velthoven V, Velkeniers B. Pituitary carcinoma - case series and review of the literature. Front Endocrinol (Lausanne). 2022;13:968692. https:\/\/doi.org\/10.3389\/fendo.2022.968692. PMID: 36157469; PMCID: PMC9493437.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"218_CR8","doi-asserted-by":"publisher","first-page":"e001532","DOI":"10.1136\/jitc-2020-001532","volume":"8","author":"N Majd","year":"2020","unstructured":"Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020;8(2):e001532. https:\/\/doi.org\/10.1136\/jitc-2020-001532. PMID: 33427689; PMCID: PMC7757504.","journal-title":"J Immunother Cancer"},{"key":"218_CR9","doi-asserted-by":"publisher","first-page":"608422","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J. The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne). 2020;11:608422. https:\/\/doi.org\/10.3389\/fendo.2020.608422. PMID: 33362722; PMCID: PMC7761748.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"218_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"PF Wang","year":"2018","unstructured":"Wang PF, Wang TJ, Yang YK, et al. The expression profile of PD-L1 and CD8\u2009+\u2009lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol. 2018;139(1):89\u201395.","journal-title":"J Neurooncol"},{"key":"218_CR11","doi-asserted-by":"publisher","unstructured":"Lin AL, Geer EB, Lala N, Page-Wilson G, Magge R, Young RJ, Tabar V. The treatment of aggressive prolactinomas with everolimus. Pituitary. 2023;26(4):474\u2013481. https:\/\/doi.org\/10.1007\/s11102-023-01340-5. PMID: 37428396.","DOI":"10.1007\/s11102-023-01340-5"},{"issue":"2","key":"218_CR12","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas","year":"2021","unstructured":"EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab. 2021;106(2):e917\u201325. https:\/\/doi.org\/10.1210\/clinem\/dgaa805. PMID: 33150390; PMCID: PMC7823257.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"218_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","volume":"61","author":"E Sosa-Eroza","year":"2018","unstructured":"Sosa-Eroza E, Espinosa E, Ram\u00edrez-Renter\u00eda C, Mendoza V, Arreola R, Mercado M. Treatment of multiresistant prolactinomas with a combination of Cabergoline and octreotide LAR. Endocrine. 2018;61(2):343\u20138.","journal-title":"Endocrine"},{"issue":"4","key":"218_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","volume":"14","author":"A Fusco","year":"2011","unstructured":"Fusco A, Lugli F, Sacco E, et al. Efficacy of the combined Cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary. 2011;14(4):351\u20137.","journal-title":"Pituitary"},{"issue":"2","key":"218_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","volume":"80","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Vasiljevic A, Borson-Chazot F, Raverot G. Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). 2019;80(2):84\u20138.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"218_CR16","doi-asserted-by":"publisher","first-page":"K21","DOI":"10.1530\/EJE-19-0279","volume":"181","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, van Meyel SWF, Pieterman KJ, et al. Excellent response to Pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019;181(2):K21\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"218_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/EC-19-0065","volume":"8","author":"G Giuffrida","year":"2019","unstructured":"Giuffrida G, Ferra\u00f9 F, Laudicella R, et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocr Connect. 2019;8(5):528\u201335.","journal-title":"Endocr Connect"},{"issue":"12","key":"218_CR18","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1210\/jcem.83.12.5300","volume":"83","author":"GA Kaltsas","year":"1998","unstructured":"Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"218_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/a-1260-3975","volume":"129","author":"K Osterhage","year":"2021","unstructured":"Osterhage K, Rotermund R, Droste M, et al. Bevacizumab in aggressive pituitary adenomas\u2014experience with 3 patients. Exp Clin Endocrinol Diabetes. 2021;129(3):178\u201385.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"218_CR20","doi-asserted-by":"publisher","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052. Epub 2017 Mar 11. PMID: 28291643.","DOI":"10.1016\/j.jocn.2017.02.052"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00218-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:03:22Z","timestamp":1744239802000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-025-00218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00218-8","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient\u2019s wife provided written consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}